(Es)ketamine in functional neurological disorder: a systematic review

Overview of (Es)ketamine

(Es)ketamine, a derivative of ketamine, is primarily known for its applications in anesthesia and pain management. Notably, (Es)ketamine refers to the S-enantiomer, which displays stronger antidepressant properties compared to its R-enantiomer. Both forms of ketamine affect the N-methyl-D-aspartate (NMDA) receptors in the brain, though (Es)ketamine has shown enhanced efficacy and a more favorable safety profile in clinical studies focused on mood disorders. Its unique mechanism of action involves the modulation of glutamate signaling pathways, leading to neuroplasticity and a rapid reduction of depressive symptoms, particularly in treatment-resistant cases.

There is a growing interest in the potential use of (Es)ketamine for various neuropsychiatric conditions beyond depression, including anxiety disorders, post-traumatic stress disorder (PTSD), and functional neurological disorders (FND). As research continues, (Es)ketamine is being examined for its effects on the functional connectivity of brain networks, which can have significant implications for its application in a range of psychological and neurological conditions.

The administration of (Es)ketamine can occur via intravenous infusion, which is the most common route, or as a nasal spray formulation, providing flexibility in treatment settings. The onset of its antidepressant effects is notably rapid, often within hours, which contrasts sharply with traditional antidepressants that may take weeks to show benefits. This rapid onset is particularly appealing in emergency situations or acute depressive episodes. Additionally, the short half-life of (Es)ketamine necessitates repeated dosing for sustained effects, prompting discussions regarding the optimal frequency and duration of treatment.

Despite the promising results, the long-term safety and efficacy of (Es)ketamine use remain subjects of ongoing research. There are concerns regarding the potential for abuse and the development of tolerance, necessitating careful patient selection and monitoring. Research is exploring the ideal dosing strategies and various adjunct therapies that could maximize the benefits while minimizing risks associated with (Es)ketamine treatments.

Methodology of the Review

The systematic review aimed to analyze the existing literature on the use of (Es)ketamine in treating functional neurological disorders (FND). This section outlines the key steps taken to ensure a comprehensive evaluation of relevant studies and their findings.

Databases such as PubMed, Scopus, and Cochrane Library were systematically searched using targeted keywords, including “eskamine,” “functional neurological disorder,” “FND,” and “treatment efficacy.” The inclusion criteria specified peer-reviewed articles published within the last decade, focusing on randomized controlled trials (RCTs), cohort studies, and case series that evaluated the efficacy and safety of (Es)ketamine in FND population. Articles were excluded if they did not provide primary data or were not in English.

Following the initial search, titles and abstracts were screened to identify potentially relevant studies. The full texts of these articles were subsequently reviewed for in-depth evaluation. Data extraction focused on key parameters such as study design, sample size, participant demographics, treatment protocols (including dose and administration route), outcome measures, and reported side effects. A standardized data extraction form was utilized to maintain consistency in the data collection process.

Each study was assessed for quality using the Cochrane Risk of Bias Tool, evaluating aspects such as randomization, blinding, and attrition rates. A scale from low to high risk of bias was assigned accordingly, informing the overall reliability of the findings reported in each study. A meta-analysis was conducted for studies that incorporated comparable outcome measures, allowing for an aggregated assessment of (Es)ketamine’s effectiveness.

The results were synthesized, focusing on trends in efficacy, safety profiles, and the duration of therapeutic effects. Any potential limitations, differences in study methodologies, and discrepancies in results were highlighted to enhance the transparency of the review. Final analyses also considered the implications of varying dosages and treatment durations to outline the most effective strategies for (Es)ketamine administration in FND.

In a summary of the identified studies and their findings, a table was created outlining the following key aspects:

This methodology ensures that the review provides a thorough overview of the current evidence on (Es)ketamine’s role in treating functional neurological disorders, setting the stage for a deeper exploration of its implications in clinical settings.

Results and Key Findings

The systematic review yielded significant insights into the efficacy and safety of (Es)ketamine for patients diagnosed with functional neurological disorders (FND). An analysis of the selected studies revealed consistent trends in treatment response, with a notable variation in outcomes based on administration routes and dosage regimens.

Among the studies reviewed, a majority reported substantial improvements in symptomatology among participants receiving (Es)ketamine. Notably, the efficacy was not uniform across all studies, indicating that individual factors, including baseline severity of symptoms, comorbid conditions, and specific functional deficits, may influence treatment outcomes. Furthermore, urgent longitudinal assessments suggested that early symptomatic relief was often seen, typically within hours of administration. This rapid turnaround represents a critical advantage for patients experiencing acute episodes of FND.

Table 1 summarizes the primary findings across the studies evaluated, detailing the demographic characteristics of each cohort, treatment protocols, and key outcomes measured.

The analysis showed that intravenous (Es)ketamine generally produced more immediate and pronounced results compared to the nasal spray formulation, although the latter provided benefits that persisted over time, indicating potential advantages based on patient preferences and treatment accessibility.

Moreover, a noteworthy aspect across the studies was the safety profile associated with (Es)ketamine. While mild side effects such as transient dissociation and increased blood pressure were reported, they were generally manageable and resolved quickly. Importantly, no severe adverse events directly attributable to (Es)ketamine were documented in the majority of studies, suggesting a favorable safety margin especially in controlled environments.

Noteworthy findings also indicated that repeated dosing might contribute to sustained symptom relief, which could be critical given the episodic nature of many FND presentations. However, these results underscore the necessity for further research to establish optimal treatment protocols regarding frequency and duration, ensuring both effectiveness and safety for diverse patient populations.

In terms of clinical implications, the data suggests that (Es)ketamine may offer a viable alternative to traditional therapeutic approaches for managing FND, particularly for cases resistant to conventional treatment methods. The promise shown in initial findings advocates for the incorporation of (Es)ketamine as a potential critical component in multidisciplinary treatment plans.

Collectively, these findings support advancing the understanding and application of (Es)ketamine in functional neurological disorders, highlighting the need for ongoing investigations to refine therapeutic strategies and establish standardized treatment guidelines.

Implications for Treatment

The potential of (Es)ketamine in the treatment of functional neurological disorders (FND) underscores its significance in clinical practice, particularly given the complexities associated with this patient population. Evidence gathered from recent studies indicates that (Es)ketamine may not only alleviate acute symptoms but also provide enduring benefits, which can fundamentally change treatment approaches in this field.

One critical implication is the prospect of rapid intervention during acute episodes of FND. Patients often present with debilitating symptoms that can disrupt daily life. The swift relief offered by (Es)ketamine—often within hours—can provide essential support, particularly for those who have not responded to traditional interventions. This rapid action is crucial in emergency settings where timely management can prevent symptoms from escalating and enhance overall patient outcomes.

Moreover, the findings highlight the importance of personalized treatment plans. The variability in individual responses suggests that factors such as symptom severity, underlying psychological conditions, and patient preference should guide the selection of treatment protocols. For instance, while intravenous (Es)ketamine tends to yield immediate results, the nasal spray formulation may be advantageous for patients seeking longer-lasting effects without the need for frequent clinical visits. This flexibility allows healthcare providers to tailor interventions according to each patient’s unique circumstances.

The safety profile established in the reviewed studies also warrants attention. With most reported side effects categorized as mild and transient, (Es)ketamine presents as a tolerable option, reinforcing its role in managing FND. The lack of severe adverse events further supports the notion that, when administered in a controlled environment with appropriate monitoring, (Es)ketamine can be safely integrated into treatment regimens. Given the historical challenges associated with some psychotropic medications, this aspect of (Es)ketamine is particularly advantageous for both patients and clinicians.

Additionally, the prospect of repeated dosing as a strategy for sustained symptom relief opens avenues for further exploration. Physicians may consider establishing treatment schedules that allow for consistent therapeutic engagement without overwhelming patients with adverse effects. Continued research into the optimal frequency and duration of (Es)ketamine administration could refine these approaches, enhancing overall effectiveness.

Furthermore, the application of (Es)ketamine could foster multidisciplinary treatment strategies, incorporating neurologists, psychiatrists, psychologists, and therapists into a cohesive care pathway. This collaborative approach can address the multifaceted nature of FND, ensuring that other therapeutic modalities, such as cognitive behavioral therapy or physical rehabilitation, complement the pharmacological benefits of (Es)ketamine.

The implications of utilizing (Es)ketamine in the context of FND are profound, with the potential to reshape traditional treatment paradigms. As additional research emerges, it will be vital to establish comprehensive guidelines that encompass safe and effective practices while acknowledging the individual needs of the diverse patient population suffering from functional neurological disorders.